Identification of somatostatin receptors using labeled PEGylated octreotide, as an active internalization

References

• Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16:86–88.
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–198.
   PubMed Web of Science ®Google Scholar
• Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–247.
   PubMed Web of Science ®Google Scholar
• Taniyama Y, Suzuki T, Mikami Y, et al. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J. 2005;52:605–611.
   PubMed Web of Science ®Google Scholar
• Hafez Abdellatif AA, Abdelhafez WA, Sarhan HA. Somatostatin decorated quantum dots for targeting of somatostatin receptors. Iran J Pharm Res. 2018;17:513–524.
   PubMed Web of Science ®Google Scholar
• Long JB. Spinal subarachnoid injection of somatostatin causes neurological deficits and neuronal injury in rats. Eur J Pharmacol. 1988;149:287–296.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836–846.
   PubMedGoogle Scholar
• Rivera JA, Alturaihi H, Kumar U. Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J Carcinog. 2005;4:10.
   PubMedGoogle Scholar
• Virgolini I, Traub T, Novotny C, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des. 2002;8:1781–1807.
   PubMed Web of Science ®Google Scholar
• Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs. 2005;19:145–163.
   PubMed Web of Science ®Google Scholar
• Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19.
   PubMed Web of Science ®Google Scholar
• Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer. 1998;76:259–266.
   PubMed Web of Science ®Google Scholar
• Reynaert H, Rombouts K, Vandermonde A, et al. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut. 2004;53:1180–1189.
   PubMed Web of Science ®Google Scholar
• Zacharias S, Singh V, Mergler S, et al. Insulinoma (Ins-1) and glucagonoma (InR1-G9) cells express pharmacologically distinctive somatostatin receptor subtypes. Eur J Endocrinol. 2005;1:152.
   Google Scholar
• Behr TM, Gratz S, Markus PM, et al. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes (''chimney sign'') in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation? Eur J Nucl Med. 1997;24:184–191.
   PubMedGoogle Scholar
• Roosterman D, Brune NEI, Kreuzer OJ, et al. Intracellular degradation of somatostatin-14 following somatostatin-receptor 3-mediated endocytosis in rat insulinoma cells. Febs J. 2008;275:4728–4739.
   PubMed Web of Science ®Google Scholar
• Wente W, Efanov AM, Treinies I, et al. The PDZ/coiled-coil domain containing protein PIST modulates insulin secretion in MIN6 insulinoma cells by interacting with somatostatin receptor subtype 5. Febs Lett. 2005;579:6305–6310.
   PubMed Web of Science ®Google Scholar
• Roosterman D, Glassmeier G, Baumeister H, et al. A somatostatin receptor 1 selective ligand inhibits Ca2+ currents in rat insulinoma 1046-38 cells. Febs Lett. 1998;425:137–140.
   PubMed Web of Science ®Google Scholar
• Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest. 1994;93:1321–1325.
   PubMed Web of Science ®Google Scholar
• Patel YC. Molecular pharmacology of somatostatin receptor subtypes. J Endocrinol Invest. 1997;20:348–367.
   PubMed Web of Science ®Google Scholar
• Abdellatif AA, El Rasoul SA, Osman S. Gold nanoparticles decorated with octreotide for somatostatin receptors targeting. Int J Pharm Sci Res. 2015;7:14–20.
   Google Scholar
• Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004;102:61–85.
   PubMed Web of Science ®Google Scholar
• Nayak T, Norenberg J, Anderson T, et al. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm. 2005;20:52–57.
   PubMed Web of Science ®Google Scholar
• Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.
   PubMed Web of Science ®Google Scholar
• Petrik M, Laznickova A, Laznicek M, et al. Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate. Anticancer Res. 2007;27:3941–3946.
   PubMed Web of Science ®Google Scholar
• Park EJ, Na DH. Optimization of octreotide PEGylation by monitoring with fast reversed-phase high-performance liquid chromatography. Anal Biochem. 2008;380:140–142.
   PubMed Web of Science ®Google Scholar
• Na DH, Lee KC, DeLuca PP. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm Res. 2005;22:743–749.
   PubMed Web of Science ®Google Scholar
• Na DH, DeLuca PP. PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co-glycolide). Pharm Res. 2005;22:736–742.
   PubMed Web of Science ®Google Scholar
• Ishihara T, Kubota T, Choi T, et al. Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness. Int J Pharm. 2009;375:148–154.
   PubMedGoogle Scholar
• Zhang YA, Wang XQ, Wang JC, et al. Octreotide-modified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells. Pharm Res. 2011;28:1167–1178.
   PubMed Web of Science ®Google Scholar
• Zhou T, Xiao X, Xu B, et al. Overexpression of SSTR2 inhibited the growth of SSTR2-positive tumors via multiple signaling pathways. Acta Oncol. 2009;48:401–410.
   PubMed Web of Science ®Google Scholar
• Abdellatif A. Octreotide labelled fluorescein isothiocyanate for identification of somatostatin receptor subtype 2. Biochem Physiol. 2015;4:2.
   Google Scholar
• Buchsbaum DJ, Rogers BE, Khazaeli MB, et al. Targeting strategies for cancer radiotherapy. Clin Cancer Res. 1999;5:3048s–3055s.
   PubMed Web of Science ®Google Scholar
• Sun LC, Coy DH. Somatostatin receptor-targeted anti-cancer therapy. CDD. 2011;8:2–10.
   PubMed Web of Science ®Google Scholar
• Tawfeek HM, Abdellatif AAH, Dennison TJ, et al. Colonic delivery of indometacin loaded PGA-co-PDL microparticles coated with Eudragit L100-55 from fast disintegrating tablets. Int J Pharm. 2017;531:80–89.
   PubMed Web of Science ®Google Scholar
• Bryant SJ, Anseth KS. Hydrogel properties influence ECM production by chondrocytes photoencapsulated in poly(ethylene glycol) hydrogels. J Biomed Mater Res. 2002;59:63–72.
   PubMed Web of Science ®Google Scholar
• Portoro I, Kocsis L, Herman P, et al. Towards a novel haemoglobin-based oxygen carrier: Euro-PEG-Hb, physico-chemical properties, vasoactivity and renal filtration. Biochim Biophys Acta. 2008;1784:1402–1409.
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Tabata Y, Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci. 1994;83:601–606.
   PubMed Web of Science ®Google Scholar
• Kinstler OB, Brems DN, Lauren SL, et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm Res. 1996;13:996–1002.
   PubMed Web of Science ®Google Scholar
• Updegrove TB, Correia JJ, Chen Y, et al. The stoichiometry of the Escherichia coli Hfq protein bound to RNA. RNA. 2011;17:489–500.
   PubMed Web of Science ®Google Scholar
• Kidwai SA, Ansari AA, Salahuddin A. Effect of succinylation (3-carboxypropionylation) on conformation and immunological activity of ovalbumin. Biochem J. 1976;155:171.
   PubMed Web of Science ®Google Scholar
• Prakash H, Mazumdar S. Succinylation of cytochrome c investigated by electrospray ionization mass spectrometry: reactive lysine residues. Int J Mass Spectrom. 2009;281:55–62.
   Web of Science ®Google Scholar
• Na DH, Murty SB, Lee KC, et al. Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery. AAPS PharmSciTech. 2003;4:574.
   Google Scholar
• Updegrove TB, Correia JJ, Chen YF, et al. The stoichiometry of the Escherichia coli Hfq protein bound to RNA. Rna—Publ RNA Soc. 2011;17:489–500.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Sugiyama T, Okano T, et al. Analysis of micelle formation of an adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer by gel permeation chromatography. Pharm Res. 1993;10:895–899.
   PubMed Web of Science ®Google Scholar
• Loret S, Nollevaux G, Remacle R, et al. Analysis of PEG 400 and 4000 in urine for gut permeability assessment using solid phase extraction and gel permeation chromatography with refractometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805:195–202.
   PubMed Web of Science ®Google Scholar
• Yan JX, Wait R, Berkelman T, et al. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis. 2000;21:3666–3672.
   PubMed Web of Science ®Google Scholar
• Pollinger K, Hennig R, Breunig M, et al. Kidney podocytes as specific targets for cyclo(RGDfC)-modified nanoparticles. Small. 2012;8:3368–3375.
   PubMed Web of Science ®Google Scholar
• Abdellatif AAH, Abou-Taleb HA, Abd El Ghany AA, et al. Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide. Saudi Pharm J. 2018;26:1162–1169.
   PubMed Web of Science ®Google Scholar
• Wilhelm P, Stephan D. On-line tracking of the coating of nanoscaled silica with titania nanoparticles via zeta-potential measurements. J Colloid Interface Sci. 2006;293:88–92.
   PubMed Web of Science ®Google Scholar
• Abdellatif AA, Tawfeek HM. Transfersomal nanoparticles for enhanced transdermal delivery of clindamycin. AAPS PharmSciTech. 2015;17:1067–1074.
   PubMed Web of Science ®Google Scholar
• Abdellatif AAH, Aldalaen SM, Faisal W, et al. Somatostatin receptors as a new active targeting sites for nanoparticles. Saudi Pharm J. 2018;26:1051–1059.
   PubMed Web of Science ®Google Scholar
• Abdellatif AAH, Tawfeek HM. Development and evaluation of fluorescent gold nanoparticles. Drug Dev Ind Pharm. 2018;44:1679–1684.
   PubMed Web of Science ®Google Scholar
• Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;10:S31–S38.
   PubMed Web of Science ®Google Scholar
• Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut. 2002;50:52–60.
   PubMed Web of Science ®Google Scholar
• Jaehde U, Masereeuw R, De Boer AG, et al. Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells. Pharm Res. 1994;11:442–448.
   PubMed Web of Science ®Google Scholar
• Knowles DB, LaCroix AS, Deines NF, et al. Separation of preferential interaction and excluded volume effects on DNA duplex and hairpin stability. Proc Natl Acad Sci USA. 2011;108:12699–12704.
   PubMed Web of Science ®Google Scholar